Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry

Clinical Research in Cardiology

Volumn 104, Issue 7, 2015, Pages 603-610

  Kornej, Jelena ^a,b   Kosiuk, Jedrzej ^a   Hindricks, Gerhard ^a   Arya, Arash ^a   Sommer, Philipp ^a   Rolf, Sascha ^a   Husser, Daniela ^a   Lip, Gregory Y H ^b   Bollmann, Andreas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Catheter ablation; Females; Renal dysfunction; Thromboembolic

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CATHETER ABLATION; DISEASE REGISTRY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; SEX RELATED PREDICTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; AGED; GERMANY; INCIDENCE; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; REGISTER; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX RATIO; STATISTICS AND NUMERICAL DATA;

AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; CAUSALITY; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; THROMBOEMBOLISM;

EID: 84933177724     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0823-6     Document Type: Article

References (29)

1. Calkins H, Kuck KH, Cappato R et al (2012) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606
2. Camm AJ, Al-Khatib SM, Calkins H et al (2012) A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J 164(292–302):e1
3. Hunter RJ, McCready J, Diab I et al (2010) Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 98:48–53
4. Bunch TJ, Crandall BG, Weiss JP et al (2011) Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 22:839–845
5. Oral H, Chugh A, Ozaydin M et al (2006) Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 114:759–765
6. Fang MC, Singer DE, Chang Y et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687–1691
7. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30:1223–1229
8. Wang TJ, Massaro JM, Levy D et al (2003) A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290:1049–1056
9. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
10. Zhang XD, Tan HW, Gu J et al (2013) Efficacy and safety of catheter ablation for long-standing persistent atrial fibrillation in women. Pacing Clin Electrophysiol 36:1236–1244
11. Kornej J, Hindricks G, Kosiuk J et al (2013) Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 6:868–874
12. Kosiuk J, Kornej J, Bollmann A et al (2014) Early cerebral thromboembolic complications following radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics and risk factors. Heart Rhythm 11:1934–1940
13. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360–1420
14. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272
15. Piccini JP, Stevens SR, Chang Y et al (2013) Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts. Circulation 127:224–232
16. Eitel C, Hindricks G, Sommer P et al (2009) Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 7:157–164
17. Calkins H, Brugada J, Packer DL et al (2007) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 9:335–379
18. Go AS, Fang MC, Udaltsova N et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369
19. Roldan V, Marin F, Manzano-Fernandez S et al (2013) Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 109:956–960
20. Meyer S, Brouwers F, Voors A, et al (2014) Sex differences in new-onset heart failure. Clin Res Cardiol (epub ahead of print)
21. Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489–496
22. Jang SJ, Kim MS, Park HJ et al (2013) Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 99:17–21
23. Rietbrock S, Heeley E, Plumb JM, Van Staa TP (2008) Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156:57–64
24. Vaccarino V, Badimon L, Corti R et al (2011) Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res 90:9–17
25. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249
26. Lowe GD (2002) Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb 32:329–332
27. Novella S, Heras M, Hermenegildo C, Dantas AP (2012) Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 32:2035–2042
28. Fradley MG, Larson MG, Cheng S et al (2011) Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 108:1341–1345
29. Hijazi Z, Oldgren J, Andersson U et al (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125:1605–1616